Goldman Sachs recently hosted the "Healthcare CEOs Unscripted" conference, and our health care analyst Max Macaluso was particularly interested in the interview with Merck's (MRK +2.54%) CEO, Kenneth Frazier. Max discusses the three takeaways he thought were most important from the talk -- including Merck's business strategy compared to the high profile spinouts recently engineered by Abbott (ABT +0.56%) and Pfizer (PFE +1.71%) -- and also offers his 2013 outlook for Merck.
